ResearcherBeckman Research InstituteActive in the last 2 years
Maurizio Pellecchia
Matched on ORCID iD 0000-0001-5179-470X; OpenAlex author ID A5039004886; NIH RePORTER profile ID 7134665. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 2
- Labs led
- 2
- Collaborators
- 10
2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper, 1 grant · 2026: 1 grant
Papers 5
- Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer. Last author DOI 10.1016/j.omton.2025.201078↗
- Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Last author DOI 10.3390/ph13050090↗
- Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Last author DOI 10.18632/oncotarget.7931↗
- The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/bs.acr.2015.04.009↗
- Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. Co-author DOI 10.1158/0008-5472.can-14-3013↗
Grants 2
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mustafa Raoof · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.51
- Giulia Alboreggia · 1 shared paper, 2025 · strength 0.25
- Paul B. Fisher · 3 shared papers, 2015–2016 · strength 0.15
- Paper Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. DOI 10.18632/oncotarget.7931↗
- Paper The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocar… DOI 10.1016/bs.acr.2015.04.009↗
- Paper Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. DOI 10.1158/0008-5472.can-14-3013↗
- Luni Emdad · 3 shared papers, 2015–2016 · strength 0.15
- Paper Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. DOI 10.18632/oncotarget.7931↗
- Paper The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocar… DOI 10.1016/bs.acr.2015.04.009↗
- Paper Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. DOI 10.1158/0008-5472.can-14-3013↗
- Bridget A. Quinn · 3 shared papers, 2015–2016 · strength 0.15
- Paper Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. DOI 10.18632/oncotarget.7931↗
- Paper The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocar… DOI 10.1016/bs.acr.2015.04.009↗
- Paper Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. DOI 10.1158/0008-5472.can-14-3013↗
- Ahmed F. Salem · 1 shared paper, 2020 · strength 0.15
- Praveen Bhoopathi · 2 shared papers, 2015 · strength 0.10
- Susan Morvaridi · 1 shared paper, 2016 · strength 0.05
- Stephen Jacob Pandol · 1 shared paper, 2016 · strength 0.05
- Siddik Sarkar · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.